Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revumenib + Chemotherapy in Relapsed/Refractory KMT2A-Rearranged Infant Leukemia
NCT05761171Phase 2Active, not recruiting
- Sponsor
- Children's Oncology Group
- Start
- Jan 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of revumenib in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Acute Leukemia Of Ambiguous Lineage (ALAL), sponsored by Children's Oncology Group. Started Jan 2024; status: active, not recruiting.
02
Drugs
revumenib
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)Acute Leukemia Of Ambiguous Lineage (ALAL)
Beyond the preview
Go deeper on NCT05761171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05761171.